Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | June 12, 2026 | June 15, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | EVP, CFO and Treasurer | February 14, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,536 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 40,011 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 38,536 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F4: This award is fully vested in accordance with its terms. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy the Brian P. McKeon Trust | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,000 F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.
F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F4: This award is fully vested in accordance with its terms.
DENTSPLY SIRONA Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy a Trust | 10,000 |
Reported balance
After 2026-06-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 10,000 · Balance 10,000 |
| Common StockSEC Table I · non-derivative | Direct | 28,887 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28,887 |
IDEXX LABORATORIES INC /DE
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,208.5926 |
Reported balance
After 2025-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-14 · Exercise / conversion · Acquired 252 · Balance 31,208.5926 F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 31,511.5926 |
Reported balance
After 2025-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-02-14 · Exercise / conversion · Acquired 303 · Balance 31,511.5926 |
| Common StockSEC Table I · non-derivative | Direct | 31,819.5926 |
Reported balance
After 2025-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-02-14 · Exercise / conversion · Acquired 308 · Balance 31,819.5926 |
| Common StockSEC Table I · non-derivative | Direct | 32,118.5926 |
Reported balance
After 2025-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-02-14 · Exercise / conversion · Acquired 299 · Balance 32,118.5926 |
| Common StockSEC Table I · non-derivative | Direct | 31,549.5926 |
Reported balance
After 2025-02-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-02-14 · Tax withholding · Disposed 569 · Balance 31,549.5926 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-14 · Exercise / conversion · Disposed 252 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 303 |
Reported balance
After 2025-02-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-14 · Exercise / conversion · Disposed 303 · Balance 303 F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 615 |
Reported balance
After 2025-02-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-14 · Exercise / conversion · Disposed 308 · Balance 615 F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 894 |
Reported balance
After 2025-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-14 · Exercise / conversion · Disposed 299 · Balance 894 F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025. |
| Common StockSEC Table I · non-derivative | Indirectby Estony McKeon Family, LLC | 18,050 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 18,050 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.
F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.
F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.
F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ATHENAHEALTH INC
Report date February 11, 2019 · Filed February 13, 2019
Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-11 transaction · row 1
1 source rowRow 1 · 2019-02-11 · Disposition to issuer · Disposed 2,721 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes. F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes.
F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:06 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | PurchaseCommon Stock | 10,000 | $10.12 | $101,200.00 |
DisclosureSEC source: 0000818479-26-000212 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By a Trust Disclosed balance after: 10,000 Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:34 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 28,887 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000189 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,887 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000090 · form4.xml · derivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: This award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,475 | $36.95 | $54,501.25 |
DisclosureSEC source: 0001520262-26-000090 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,536 Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000090 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000090 · form4.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F3 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000090 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F3 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016203 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:32 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,924 | $30.61 | $58,893.64 |
DisclosureSEC source: 0001127602-25-016203 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,869 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016203 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015542 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015542 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 299 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894 Underlying: Common Stock · 299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615 Underlying: Common Stock · 308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 303 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303 Underlying: Common Stock · 303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 569 | $444.53 | $252,937.57 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,549.5926 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 299 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,118.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,819.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 303 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,511.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000031 · wk-form4_1739933050.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,208.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F3 · price: Not applicable F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 117 | $455.08 | $53,244.36 |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,931.5926 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 192 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000124 · wk-form4_1723064478.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,048.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: (1) Includes a total of 22 shares purchased under the Issuer's Employee Stock Purchase Plan on March 29, 2024 and June 28, 2024. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019599 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,465 | $24.10 | $35,306.50 |
DisclosureSEC source: 0001127602-24-019599 · form4.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,780 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019599 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017729 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017729 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0000874716-24-000047 · wk-form4_1708466405.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-24-000047 · wk-form4_1708466405.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,834.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923 Underlying: Common Stock · 308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 303 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606 Underlying: Common Stock · 303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252 Underlying: Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 432 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,193 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193 Underlying: Common Stock · 1,193 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,355 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,355 Underlying: Common Stock · 5,355 shares Expires 2034-02-13 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,097 | $560.56 | $614,934.32 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,351.5926 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,448.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 303 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,140.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,837.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 432 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,584.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000040 · wk-form4_1708124209.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,152.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: This award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,088 | $27.32 | $29,724.16 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,141 Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 23,326 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,326 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 681 | $572.80 | $390,079.59 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,717.5926 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $572.42 to a high of $573.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.